Premium
Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single‐centre experience in 303 patients
Author(s) -
Zervas Kostas,
Verrou Evgenia,
Teleioudis Zisis,
Vahtsevanos Konstantinos,
Banti Anastasia,
Mihou Dimitra,
Krikelis Dimitris,
Terpos Evangelos
Publication year - 2006
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2006.06230.x
Subject(s) - zoledronic acid , thalidomide , medicine , osteonecrosis of the jaw , multiple myeloma , bisphosphonate , incidence (geometry) , diphosphonates , surgery , osteoporosis , bone resorption , physics , optics
Summary The incidence, characteristics and risk factors for the development of osteonecrosis of the jaw (ONJ) were evaluated among 303 myeloma patients. Only patients who received bisphosphonates developed ONJ (28/254; 11%). Zoledronic acid produced 9·5‐fold greater risk for developing ONJ than pamidronate alone ( P = 0·042) and 4·5‐fold greater risk than subsequent use of pamidronate + zoledronic acid ( P = 0·018). Use of thalidomide and number of bisphosphonate infusions also increased the risk for ONJ by 2·4‐fold ( P = 0·043), and 4·9‐fold respectively ( P = 0·012). ONJ developed earlier among patients receiving zoledronic acid. Our data indicates that administration of zoledronic acid for more than 2 years or in combination with thalidomide requires caution in myeloma.